Precision medicine

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Earns CDE Breakthrough Therapy Status

Fineline Cube Jun 13, 2022

China-based InventisBio (Shanghai) Co., Ltd announced receiving breakthrough therapy designation (BTD) status for its KRAS...

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging